MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Authors
Keywords
Merestinib, Emibetuzumab, MET exon 14 skipping, MET kinase inhibitor, MET antibody, LY2801653, LY2875358
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2017-11-29
DOI
10.1007/s10637-017-0545-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
- (2017) Chien-Hung Gow et al. LUNG CANCER
- Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
- (2016) Jieyi Wang et al. BMC CANCER
- Gene aberrations for precision medicine against lung adenocarcinoma
- (2016) Motonobu Saito et al. CANCER SCIENCE
- ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
- (2016) Jieyi Wang et al. CLINICAL CANCER RESEARCH
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- cMET Exon 14 Skipping: From the Structure to the Clinic
- (2016) Nele Van Der Steen et al. Journal of Thoracic Oncology
- Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
- (2016) Rebecca S. Heist et al. Journal of Thoracic Oncology
- Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
- (2016) Shiyong Li et al. Journal of Thoracic Oncology
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations
- (2016) Hua-Jie Dong et al. LUNG CANCER
- MET Exon 14 Skipping in Non-Small Cell Lung Cancer
- (2016) Rebecca S. Heist et al. ONCOLOGIST
- Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
- (2016) M. Bahcall et al. Cancer Discovery
- Skipping the line: bringing MET exon 14 skipping mutations to the forefront of targeted therapy
- (2016) Elaine Shum et al. Translational Cancer Research
- Signalling to eIF4E in cancer
- (2015) N. Siddiqui et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Gastrointestinal malignancies harbor actionable MET exon 14 deletions
- (2015) Jeeyun Lee et al. Oncotarget
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
- (2014) Z. Zhang et al. CLINICAL CANCER RESEARCH
- The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer
- (2014) C. Egile et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
- (2013) W. Wu et al. CLINICAL CANCER RESEARCH
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
- (2012) J M Lee et al. ONCOGENE
- Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
- (2010) Yoshinari Asaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
- (2010) Giovanni Pacchiana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started